11月11日，Recursion Pharmaceuticals, Inc.盘前上涨5.07%，报3.73美元/股，成交额158.14万美元。
消息面上，公司最新披露REC-4881项目二期数据，显示家族性腺瘤性息肉病患者息肉负担明显下降，且安全性表现较为清洁，并支持推进注册性试验，成为股价异动的主要催化。
此前公司还宣布由资深医药行业高管Fred Hassan出任董事长，并在三季度录得营收1855万美元、净亏损1.19亿美元。市场当前更关注其AI药物发现平台能否借助REC-4881的临床进展，推动后续估值修复。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.